Standard BioTools (LAB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company that makes equipment to control fluids would post a loss of $0.09 per share when it actually produced a loss of $0.23, delivering a surprise of -155.56%. Over the ...

Management Changes - Jeffrey Black, Chief Financial Officer, will resign effective August 31, 2024, to pursue another opportunity [1] - Alex Kim, Chief Operating Officer and co-founder, will serve as interim Chief Financial Officer starting September 1, 2024 [1] - Sean Mackay, recently appointed Chief Business Officer, will take on additional responsibilities including product management, marketing, and investor relations [2] Leadership Statements - Michael Egholm, President and CEO, expressed confidence in Alex Kim's leadership and strategic planning capabilities for the interim CFO role [3] - Egholm acknowledged Jeffrey Black's contributions to building a strong finance function and wished him well in his future endeavors [3] - Black expressed pride in his time at Standard BioTools and confidence in the company's future success [3] Company Overview - Standard BioTools Inc. (Nasdaq: LAB) is known for its next-generation technologies that aid biomedical researchers in developing medicines [5] - The company focuses on providing insights in health and disease through proprietary mass cytometry and microfluidics technologies [5] - Standard BioTools collaborates with various research and clinical laboratories globally, addressing needs in translational and clinical research, particularly in oncology and immunology [5]

MEXICO CITY, July 22, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), a leading company in the pharmaceutical and personal care industry in Mexico with a growing international presence, announces that it has secured a long-term credit line, refinanced financial liabilities, and obtained the release of real estate collateral tied to existing loans. Long-Term Credit Line with BANCOMEXT The Company secured an amortizable credit line of MXN $1,500 mil ...

US domestic callers: (888) 346-3970 Outside US callers: (412) 902-4297 Investor Contact: SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on July 31, 2024, to discuss second quarter 2024 finan ...

Core Viewpoint - Standard BioTools Inc. is set to report its second quarter 2024 financial results on July 31, 2024, after market close, indicating ongoing operational progress and financial performance tracking [1]. Group 1: Financial Reporting - The company will announce its second quarter 2024 financial results on July 31, 2024, after the market closes [1]. - A conference call and webcast will be hosted by the company's management at 1:30 p.m. PT, 4:30 p.m. ET on the same day to discuss the financial results and operational progress [2]. Group 2: Company Overview - Standard BioTools Inc. (Nasdaq: LAB), formerly known as Fluidigm Corporation, specializes in next-generation technologies that aid biomedical researchers in developing medicines more efficiently [4]. - The company utilizes proprietary mass cytometry and microfluidics technologies to provide reliable insights in health and disease, focusing on translational and clinical research in areas such as oncology, immunology, and immunotherapy [4].

Core Points - Genomma Lab Internacional, S.A.B. de C.V. has declared a cash dividend of $0.20 Mexican pesos per share, totaling $200 million pesos, payable to shareholders on June 21, 2024 [8] - The dividend per share represents a 2% increase compared to the previous quarter, attributed to the cancellation of 20 million shares approved at the last Annual General Shareholders Meeting (AGSM) [1][3] - The company intends to make dividend payments on a quarterly basis, subject to the terms established by the AGSM [4] Company Overview - Genomma Lab is one of the fastest-growing pharmaceutical and personal care products companies in Latin America, developing and marketing a wide range of premium branded products that are leaders in their respective categories [5] - The company operates a sound business model characterized by a unique combination of new product development, consumer-oriented marketing, a broad retail distribution network, and a low-cost, flexible supply chain [5] - Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" [5]

SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument will enable Standard BioTools™ to further validate its SomaScan® Platform by measuring the kinetic properties of SOMAmer® Reagents and deliver precise information about protein binding and biomarker chara ...

Core Insights - Standard BioTools Inc. has acquired the LSAXT system from Carterra to enhance the validation of its SomaScan Platform, which focuses on measuring kinetic properties of SOMAmer Reagents and providing detailed information on protein binding and biomarker characterization [1][2][3] Company Overview - Standard BioTools Inc. (Nasdaq:LAB), formerly known as Fluidigm Corporation, specializes in next-generation technologies that aid biomedical researchers in developing medicines more efficiently. The company utilizes proprietary mass cytometry and microfluidics technologies to deliver reliable insights in health and disease [4] - Carterra is a leading provider of high-throughput technologies aimed at accelerating the discovery of novel therapeutic candidates. Its LSAXT system is designed to deliver significantly higher throughput and efficiency compared to existing platforms [6] Product and Technology Details - The SomaScan Platform is a high-throughput proteomics technology that allows comprehensive analysis of proteomic biomarkers, enhancing the research capabilities for scientists [2] - The LSAXT system will be instrumental in verifying the quality of SomaScan 11K Assay reagents and will support future content expansion of the platform, thereby increasing its value to researchers [2][3] - The LSAXT system is noted for its ability to provide more data in a shorter time frame, which will help Standard BioTools identify precise binding sites on proteins and discover new biomarkers [3] Leadership Statements - The CEO of Carterra expressed enthusiasm about the collaboration with Standard BioTools, emphasizing the importance of measuring kinetic properties for a deeper understanding of reagent-protein interactions [3] - The President and CEO of Standard BioTools highlighted the focus on ensuring precision and specificity in the SomaScan Platform, which will be enhanced by the capabilities of the LSAXT system [4]

Group 1 - Standard BioTools Inc. will participate in several investor conferences in June 2024, including the Jefferies Global Healthcare Conference and the TD Cowen's 3rd Annual Tool/Dx Revolution Conference [1][4] - The company is known for its portfolio of next-generation technologies that aid biomedical researchers in developing medicines more efficiently [2] - Standard BioTools focuses on providing insights in health and disease through its proprietary mass cytometry and microfluidics technologies, addressing needs in translational and clinical research, particularly in oncology and immunology [2] Group 2 - The President and CEO, Michael Egholm, PhD, will engage in a fireside chat at the Jefferies Global Healthcare Conference on June 5th and participate in a panel discussion at the TD Cowen's conference on June 25th [4] - The company has a strong presence in various research sectors, including academic, government, pharmaceutical, and biotechnology, emphasizing its role in improving patient outcomes [2]

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools") (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Available presentations will be webcast live and available on the Investor Relations page of the Company's website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com. About Stan ...